Regular Drug Eluting Stent Versus Dedicated Bifurcation Sirolimus-eluting Stent BiOSS LIM in Coronary Bifurcation Treatment - Randomized POLBOS II Study.
Overview
- Phase
- Phase 4
- Intervention
- Dual antipletlet therapy (DAPT)
- Conditions
- Coronary Artery Disease
- Sponsor
- Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
- Enrollment
- 202
- Locations
- 1
- Primary Endpoint
- MACE
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Coronary bifurcation lesions pose therapeutic problems during percutaneous coronary interventions (PCI) and are associated with higher rates of periprocedural complications as well as higher rates of in-stent restenosis and stent thrombosis. Provisional T-stenting (PTS) is the best treatment strategy at the moment. However, the optimal approach to coronary bifurcations treatment is still a subject of debate, especially when the side branch is large, not easily accessible and narrowed by a long lesion. One of the proposed alternatives are dedicated bifurcation stents (DBS). However, there is large scarcity of randomized trials with DBS. POLBOS II study is continuation of POLBOS I (POLish Bifurcation Optimal Stenting) study, in which paclitaxel-eluting stent BiOSS Expert® (Balton, Poland) was assessed. Now performance of sirolimus-eluting stent BiOSS LIM® (Balton, Poland) is verified.
Detailed Description
After signing the informed consent patients were randomly assigned to one of two treatment strategies: BiOSS LIM® stent implantation or rDES implantation (envelope randomization, 1:1). If the patient was enrolled to rDES Group there was a second randomization: with or without final kissing ballooning (FKB). Clinical follow-up was performed with office visits or telephone contacts at 1 and 12 months after intervention. Adverse events were monitored throughout the study period. Follow-up coronary angiography was performed at 12 months unless clinically indicated earlier.
Investigators
Jacek Bil
MD, PhD
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
Eligibility Criteria
Inclusion Criteria
- •stable coronary artery disease (CAD) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
- •age ≥ 18 years old,
- •de novo coronary bifurcation lesion (including unprotected LMS),
- •MV diameter ≥ 2.5 mm and SB diameter ≥ 2.0 mm assessed by visual estimation.
Exclusion Criteria
- •ST-elevation myocardial infarction (STEMI),
- •bifurcations with Medina type 0,0,1,
- •serum creatinine level ≥ 2.0 mg/dl,
- •inability to take dual antiplatelet therapy for 12 months,
- •left ejection fraction ≤ 30%
- •lack of an informed consent
Arms & Interventions
BiOSS LIM Group
BiOSS LIM® stent implantation into coronary lesion within bifurcation.
Intervention: Dual antipletlet therapy (DAPT)
rDES Group
regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
Intervention: Coronary angioplasty with stent implantation
rDES Group
regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
Intervention: Dual antipletlet therapy (DAPT)
BiOSS LIM Group
BiOSS LIM® stent implantation into coronary lesion within bifurcation.
Intervention: Coronary angioplasty with stent implantation
Outcomes
Primary Outcomes
MACE
Time Frame: 12 months
Cumulative rate of major adverse cardiovascular events (MACE) including cardiac death, myocardial infarction (MI) and repeated revascularization of the target lesion (TLR)
Secondary Outcomes
- all-cause death(12 months)
- LLL(12 months)
- cardiac death(12 months)
- MI(12 months)
- TLR(12 months)
- TVR(12 months)